Collaborations

Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent

The first phase of the joint research activities with Georgetown, which began in the 4th quarter of 2019, generated strong evidence of the efficacy of LP-184 in prostate cancer and linked the anti-tumor activity to the presence of specific biomarkers. Phase one of the collaboration was a proof-of-concept study that demonstrated LP-184 had nanomolar potency across a wide variety of cell lines, as well as Prostate Cancer Organoids. In the next phase, gene centric studies have been conducted to precisely delineate the synthetic lethality of LP-184s efficacy in killing prostate cancer cells that have deficiency in Homologous recombination and Nucleotide Excision repair pathways. These studies strongly demonstrate that LP184 is an highly efficacious molecule for treatment of prostate cancers that overexpress PTGR1 and carry mutations in DNA damage repair genes including BRCA2, ERCC6 and others involved in homologous recombination and Nucleotide Excision repair.‍

Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center (DCRC) to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors

The collaboration is expected to examine the most common solid tumors in order to determine the patient populations most likely to benefit from Lantern’s drug candidates LP-100 (irofulven) and LP-184. LP-100 and LP-184 have both shown to have a synthetically lethal impact in tumors that are lacking nucleotide excision repair (NER) capabilities. An additional aim of this collaboration will be to develop improved diagnostic tools to detect NER deficient patient profiles more accurately. Lantern expects the data, genomic signatures, and biological models generated from the collaboration to add millions of data points to RADR®. Dr. Zoltan Szallasi, M.D. will lead the collaboration for the DCRC.